Autor: |
Al‐Sawaf, O., Robrecht, S., Zhang, C., Olivieri, S., Chang, Y. M., Fink, A. M., Tausch, E., Schneider, C., Ritgen, M., Kreuzer, K., Sivcheva, L., Niemann, C., Schwarer, A., Loscertales, J., Weinkove, R., Strumberg, D., Kilfoyle, A., Runkel, E. D., Eichhorst, B., Stilgenbauer, S. |
Předmět: |
|
Zdroj: |
Hematological Oncology; Jun2023 Supplement 1, Vol. 41, p58-60, 3p |
Abstrakt: |
Progressive disease (PD) occurred in 67 cases in the Ven-Obi arm with 39 second-line treatments, and in 141 cases in the Clb-Obi arm (with 103 second-line treatments). B Background: b One-year fixed-duration venetoclax-obinutuzumab (Ven-Obi) is a standard-of-care for patients (pts) with previously untreated chronic lymphocytic leukemia (CLL). Overall, 48 deaths were reported in the Ven-Obi arm (9 PD related) and 70 in the Clb-Obi arm (26 PD related); 6-year-OS rate was 78.7% in the Ven-Obi and 69.2% in the Clb-Obi arm (HR 0.69 [0.48-1.01], I p i = 0.052). [Extracted from the article] |
Databáze: |
Complementary Index |
Externí odkaz: |
|